TNDM
T3Tandem Diabetes Care, Inc.
OverviewTandem Diabetes Care, Inc. develops and commercializes insulin delivery systems, including the t:slim X2 and Mobi pumps, along with advanced automated insulin d
Tandem Diabetes Care, Inc. develops and commercializes insulin delivery systems, including the t:slim X2 and Mobi pumps, along with advanced automated insulin delivery algorithms like Control-IQ+. Serving nearly 0.5 million customers globally, the company targets individuals with insulin-dependent type 1 and type 2 diabetes. Tandem is transitioning to a pay-as-you-go model in the U.S. pharmacy channel and expanding direct international operations, aiming to enhance accessibility and profitability.
- What They Do (Plain English & Analogies)
- Tandem Diabetes Care is a medical device company that creates smart insulin pumps and automated insulin delivery (AID) systems for people with diabetes who need insulin. Think of their products like a 'smart thermostat' for your body: they continuously monitor glucose levels (through integration with other devices) and automatically adjust insulin delivery to help keep blood sugar in a healthy range. They offer both traditional tubed pumps and are expanding into smaller, tubeless patch pumps.
- Very Brief History
- Tandem Diabetes Care, Inc. was founded in 2006 as Phluid Inc. and rebranded to its current name in 2008. The company launched its first touchscreen insulin pump, the t:slim, in 2011. A significant milestone was the commercial release of its Control-IQ automated insulin delivery technology in 2020. In 2023, they received FDA clearance for their compact Mobi pump, which commercially launched in the U.S. in February 2024. By 2025, the company had surpassed $1 billion in annual sales.
- "Street Stereotype"
- Tandem Diabetes Care is generally perceived as an innovative player in the diabetes device market, known for its advanced automated insulin delivery (AID) systems. However, the broader 'Medical Devices & Monitoring' sector, including diabetes management, faces a 'bearish' sentiment due to the rise of GLP-1 drugs, which could potentially reduce the need for some devices. [cite: GLP-1 Short '24: Medical Devices & Monitoring] Despite this, Tandem is seen as a company making bold, transformative strategic moves, such as the new PayGo model and an expanding product pipeline, to drive future growth and profitability.
- Customer Sectors & Example Clients
- Tandem's customer sectors include individual patients living with insulin-dependent diabetes (Type 1 and Type 2), their caregivers, healthcare providers (e.g., endocrinologists, diabetes educators, clinics, hospitals), and payers (insurance companies and government health programs). While specific client companies are not named, Tandem's business model involves partnerships with Continuous Glucose Monitoring (CGM) providers such as Dexcom, Inc. and Abbott Laboratories for integrated system functionality.
- New Customers / Segments They'Re Targeting
- Tandem is actively targeting several new customer segments and markets: 1. **Adults with Type 2 Diabetes:** They are expanding their commercial efforts for people living with Type 2 diabetes, which doubles their addressable market. 2. **Patch Pump Users:** With the upcoming launch of Mobi Tubeless, they are targeting individuals who prefer a tubeless, patch-pump form factor. 3. **International Markets:** The company is expanding its direct commercial operations in key international markets, starting with the U.K., Switzerland, and Austria in Q1 2026, with plans for further expansion in 2026 and 2027. 4. **Pharmacy Channel Customers:** They are accelerating efforts to increase pharmacy coverage and utilization of a 'pay-as-you-go' (PayGo) reimbursement model, aiming to attract customers seeking lower out-of-pocket costs and easier onboarding.
- How Key Themes May Help/Hurt
- The 'GLP-1 Short '24: Medical Devices & Monitoring' theme suggests that the advent of GLP-1 drugs could negatively impact companies manufacturing devices for diabetes management. [cite: GLP-1 Short '24: Medical Devices & Monitoring] This could hurt Tandem by potentially reducing the overall population requiring insulin pumps or delaying the initiation of insulin therapy for some Type 2 diabetes patients due to improved glycemic control and weight loss from GLP-1s. However, Tandem's strategy to expand into the Type 2 diabetes market with Control-IQ+ may help mitigate this. Clinical studies have shown that Control-IQ+ technology can significantly improve A1C even in people using GLP-1 receptor agonists, suggesting a synergistic benefit rather than a complete replacement. The continued need for intensive insulin management for Type 1 diabetes patients and many Type 2 patients, regardless of GLP-1 use, also provides a sustained market. [cite: GLP-1 Short '24: Medical Devices & Monitoring]
3 Main Long-Term Bull Details
- Transformative Pay-as-you-go (PayGo) Business Model: The strategic shift to a pharmacy-based PayGo reimbursement model is expected to significantly reduce upfront costs for patients, improve accessibility, and streamline the prescription process. This is anticipated to accelerate pump adoption, drive market expansion, and ultimately lead to higher lifetime revenue per customer, strengthening the business model for sustainable growth and profitability.
- Robust and Differentiated Product Pipeline: Tandem boasts an exciting pipeline, including the imminent launch of Mobi Tubeless (the world's first patch pump with extended wear technology), further miniaturization with Sigi technology, dual glucose ketone sensor integration, and a pivotal trial for a fully closed-loop AID system by 2027. These innovations are designed to redefine pump wearability and enhance clinical outcomes.
- Expanding Addressable Market and International Reach: The Control-IQ+ algorithm's indication for adults with Type 2 diabetes significantly doubles Tandem's addressable market. Coupled with the expansion of direct commercial operations into key international markets, which is expected to yield higher average selling prices (ASPs) and deeper customer relationships, these initiatives are poised to drive substantial long-term growth.
3 Main Long-Term Bear Details
- Near-term Financial Headwinds and Moderated Growth: The transition to the PayGo model and direct international operations will result in significant revenue headwinds and moderated sales growth in 2026. This is due to the shift from upfront pump revenue recognition to recurring supply revenue and the impact of distributor destocking, creating short-term financial pressure.
- Intense Competitive Landscape: Tandem operates in a highly competitive market, facing strong rivals such as Medtronic and Insulet, particularly Insulet's established leadership in the tubeless patch pump segment. Sustaining and growing market share will require continuous innovation, effective commercial strategies, and successful differentiation against these competitors.
- Potential Impact of GLP-1 Receptor Agonists: Despite Tandem's efforts to show synergy, the increasing adoption and efficacy of GLP-1 drugs for Type 2 diabetes and obesity could still pose a long-term risk. These drugs may reduce the overall population requiring insulin pumps or delay the initiation of insulin therapy for some patients, potentially limiting Tandem's market growth in the Type 2 segment. [cite: GLP-1 Short '24: Medical Devices & Monitoring, 12]
- Competitors And Differentiation
- Tandem's primary competitors in the insulin pump market include Medtronic (with its MiniMed systems) and Insulet (known for its tubeless Omnipod patch pump). Tandem differentiates itself through: 1. **Advanced Automated Insulin Delivery (AID) Algorithm:** Their Control-IQ+ technology is indicated for Type 1 diabetes (down to age 2) and adults with Type 2 diabetes, designed for ease of use and with clinical evidence to simplify carb counting. 2. **Diverse Pump Portfolio:** Offering both the t:slim X2 (a tubed pump) and the compact Mobi pump, with the upcoming Mobi Tubeless providing the world's first patch pump with extended wear technology and interchangeability between tubed and tubeless wear on one platform. 3. **CGM Integration:** Strong partnerships and integration with leading continuous glucose monitoring (CGM) systems like Dexcom and Abbott's FreeStyle Libre 3 Plus. 4. **Customer Experience and Affordability:** A focus on user-centric design, software updates, and the new 'pay-as-you-go' pharmacy model to improve affordability and accessibility for patients.
- Recent Performance & What The Market'S Focused On
- Tandem Diabetes Care delivered a strong performance in 2025, surpassing $1 billion in worldwide sales, marking its second consecutive year of double-digit growth (12% worldwide, 10% U.S., 15% international). The fourth quarter of 2025 was a record-setting period with $290 million in worldwide sales (15% year-over-year growth), the highest quarterly pump shipments, an expanded gross margin of 58%, and the first positive operating margin since 2021 at 3%. The market is primarily focused on the company's strategic transition to a 'pay-as-you-go' (PayGo) reimbursement model in the pharmacy channel. This transition is expected to create $85 million to $95 million in total sales headwinds for 2026, leading to moderated sales growth guidance for the year. Investors are closely monitoring pump shipments as a key indicator of market expansion, the scaling of pharmacy access, the progress of new product launches like Mobi Tubeless, and the expansion of direct international operations, all of which are expected to drive accelerated growth and profitability in 2027 and beyond.
- Brands And Revenue Segments
- Brands: t:slim X2, Mobi, Control-IQ+, Basal-IQ, t:connect, Sugarmate, Mobi Tubeless (upcoming), SteadiSet (upcoming), Sigi technology (future miniaturization). Revenue Segments (2025): * **U.S. Sales:** $707 million * **International Sales:** $308 million * **Worldwide Sales:** Over $1 billion
Bull / Bear DetailsTandem Diabetes Care is poised for long-term growth and profitability, driven by its strategic shift to a pay-as-you-go pharmacy model in the U.S. and direct in
Thesis
Tandem Diabetes Care is poised for long-term growth and profitability, driven by its strategic shift to a pay-as-you-go pharmacy model in the U.S. and direct international expansion. These initiatives, alongside a robust product pipeline including Mobi Tubeless and Control-IQ+ for Type 2 diabetes, are expected to enhance market accessibility and patient retention, offsetting near-term revenue moderation. The bullish case is compelling as of 2026-03-03, with significant margin expansion and accelerated growth anticipated from 2027.
Bull case
The transition to a pay-as-you-go (PayGo) pharmacy model in the U.S. is a significant long-term growth driver. It eliminates upfront pump costs for patients, streamlines prescriptions, and is expected to more than double lifetime revenue per patient for Tandem, leading to accelerated sales growth and enhanced profitability from 2027.
Tandem boasts an exciting product pipeline, including the recent launch of Control-IQ+ for Type 2 diabetes (doubling addressable market) and the anticipated Mobi Tubeless (first extended wear patch pump) in H2 2026. Multiple sensor integrations and international Mobi launches further strengthen its competitive position and drive new pump shipments.
Direct international operations in key European markets, initiated in 2026, are expected to yield at least 30% higher average selling prices (ASPs) compared to prior distributor models. This, combined with product cost reductions and operational efficiencies, is projected to drive meaningful gross margin expansion to 60% by Q4 2026 and 65% long-term.
Bear case
The strategic shift to the PayGo model and international direct operations will create significant near-term revenue headwinds in 2026, estimated at $85 million to $95 million worldwide. This moderation in sales growth, coupled with the complexities of transitioning existing customers and establishing new reimbursement structures, poses execution risks.
While Tandem is expanding its market, the broader medical device industry faces potential headwinds from GLP-1 drugs reducing the need for diabetes management devices. Intense competition in the insulin pump market, including new patch pump offerings, could pressure market share and pricing despite Tandem's innovation.
The success of the PayGo model hinges on rapid pharmacy channel penetration and consistent reimbursement rates. Achieving the targeted 70% pharmacy sales in 2-3 years and maintaining the expected $350 per month per customer reimbursement could be challenging due to varying payer contracts and patient adoption rates.
Bull / Bear Case
- Bear Case
- The strategic shift to the PayGo model and direct international operations will create significant near-term revenue headwinds in 2026, estimated at $85 million to $95 million worldwide. This moderation in sales growth, coupled with the complexities of transitioning existing customers and establishing new reimbursement structures, poses substantial execution risks. The company is currently unprofitable, with negative EPS, EBITDA, and Free Cash Flow, and anticipates negative adjusted EBITDA in Q1 2026. Additionally, the broader medical device industry faces potential headwinds from GLP-1 drugs, which could reduce demand for diabetes management devices, and intense competition in the insulin pump market could pressure market share and pricing.
- Bull Case
- Tandem Diabetes Care is poised for long-term growth and profitability, driven by its strategic shift to a pay-as-you-go (PayGo) pharmacy model in the U.S. This model is expected to eliminate upfront pump costs for patients, streamline prescriptions, and more than double lifetime revenue per patient for Tandem, leading to accelerated sales growth and enhanced profitability from 2027. The company boasts an exciting product pipeline, including the recently launched Control-IQ+ for Type 2 diabetes (doubling the addressable market) and the anticipated Mobi Tubeless, the world's first extended wear patch pump, expected in H2 2026. Direct international operations in key European markets are projected to yield at least 30% higher average selling prices, contributing to meaningful gross margin expansion to 60% by Q4 2026 and a long-term target of 65%.
- More Compelling & Why
- Bear. Tandem Diabetes Care's current unprofitability, evidenced by negative EV/EBITDA and Free Cash Flow Yield, makes its valuation less compelling despite a lower Price/Sales ratio compared to peers. The strongest argument for the bear case is the significant near-term revenue headwinds of $85 million to $95 million in 2026 due to the PayGo transition, coupled with the inherent execution risks of such a fundamental business model shift and expected negative adjusted EBITDA in Q1 2026. My view would flip if the company demonstrates faster-than-expected pharmacy penetration and a quicker return to consistent profitability and positive free cash flow, mitigating the near-term revenue impact.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| CMS Decision on C-peptide Testing for Type 2 Diabetes | A favorable decision from CMS would substantially improve Medicare's access to pump technology for Type 2 diabetes, a market segment that doubles Tandem's addressable market and is a key focus for commercial expansion. | CMS announcement or update on the review of the National Coverage Determination (NCD) for insulin pumps related to C-peptide testing, specifically by August 2026; Any changes in Medicare coverage policies for insulin pumps for Type 2 diabetes patients. | Bullish: CMS decision to remove or significantly relax C-peptide testing requirements, leading to broader Medicare coverage for Type 2 diabetes patients using insulin pumps. Bearish: CMS decision to maintain or strengthen existing C-peptide testing requirements, limiting Medicare access for Type 2 diabetes patients. | CMS official announcements, ADA (American Diabetes Association) news, industry trade publications, Tandem Diabetes Care's investor relations updates. | Government websites (CMS.gov), diabetes advocacy group press releases. | |
| Mobi Tubeless FDA 510(k) Submission and Launch | Mobi Tubeless represents Tandem's entry into the patch pump market, offering a novel form factor with extended wear technology and Control-IQ+ algorithm. This expands Tandem's addressable market and directly competes with existing patch pump solutions. | Announcement of 510(k) submission to the FDA in Q2 2026; Announcement of FDA clearance for Mobi Tubeless; Announcement of commercial launch timing and initial market availability in H2 2026. | Bullish: Timely 510(k) submission in Q2 2026, followed by FDA clearance and commercial launch in H2 2026 as planned or earlier. Positive early feedback on product adoption and sales. Bearish: Delays in 510(k) submission or FDA clearance, or a postponed launch beyond H2 2026. | Tandem Diabetes Care's press releases, investor relations updates, FDA 510(k) database. | FDA 510(k) clearances database, diabetes patient forums/subreddits for early user reviews. | Thinknum: Tandem job postings for 'Mobi Tubeless' sales/marketing roles. |
| Q2 2026 Product Launches/Integrations | These launches enhance Tandem's product portfolio, expand market reach for Mobi, and offer greater sensor integration flexibility, which are critical drivers for new pump shipments and overall market expansion. | Confirmation of successful launches for Mobi internationally, Mobi integration with FreeStyle Libre 3 Plus in the U.S., and Dexcom's 15-day sensor integration globally in Q2 2026; Updates on pump shipment growth, particularly new pump growth led by MDI conversions (expected 10-11% year-over-year increase in U.S. pump shipments for 2026). | Bullish: Timely and successful launches in Q2 2026, contributing to strong pump shipment growth and positive market reception. Bearish: Delays in any of these key product launches or integrations, or weaker-than-expected impact on pump shipments. | Tandem Diabetes Care's press releases, investor presentations, and quarterly earnings calls. | Diabetes technology news sites, patient forums, social media discussions about new product availability and features. | Apptopia/Sensor Tower: Download and usage trends for Tandem's mobile apps (e.g., t:connect, Sugarmate) in relevant regions, especially after new integrations. |
| U.S. Pay-as-you-go (PayGo) Model Rollout & Pharmacy Penetration | This strategic shift eliminates upfront pump payments for customers, reduces out-of-pocket costs, and provides Tandem with greater economic reimbursement and a more predictable, higher-value revenue stream over time, driving market expansion and long-term profitability. | Percentage of U.S. pump shipments through the pharmacy channel (expected to average ~20% for 2026); Percentage of existing U.S. installed base ordering supplies through pharmacy (expected to average ~10% for 2026); Updates on U.S. sales guidance, particularly regarding the $70M-$80M pricing headwinds and the expected $350 per month per customer reimbursement rate. | Bullish: Pharmacy penetration rates (both new pump shipments and existing customer supply orders) exceeding 20% and 10% respectively for 2026, or upward revisions to U.S. sales guidance due to faster PayGo adoption and higher reimbursement rates. Bearish: Pharmacy penetration rates falling short of 20% and 10% for 2026, or downward revisions to U.S. sales guidance due to slower PayGo adoption or lower-than-expected reimbursement. | Tandem Diabetes Care's quarterly earnings calls and press releases, Form 10-K and 10-Q filings. | Google Trends: 'Tandem PayGo', 'Tandem pharmacy pump'. | IQVIA: Prescription data for Tandem pumps through pharmacy channels. |
| International Direct Operations Expansion | Expanding direct operations internationally allows Tandem to deepen relationships with the diabetes community, capture higher Average Selling Prices (ASPs) (expected at least 30% higher), and improve gross margins, contributing to overall international sales growth. | Announcements regarding the specific European markets targeted for direct transition in Q4 2026; Updates on international sales growth, particularly the impact of ASP premiums and distributor destocking ($15M anticipated headwind for 2026); International sales expected to be $335M-$340M for 2026, with direct sales representing ~15% of total international sales for the full year. | Bullish: Successful and timely transitions to direct operations in Q4 2026, with international sales and ASPs meeting or exceeding guidance, and effective mitigation of destocking headwinds. Bearish: Delays in market transitions, lower-than-expected ASP premiums, or greater-than-anticipated impact from distributor destocking. | Tandem Diabetes Care's quarterly earnings calls and press releases, Form 10-K and 10-Q filings. | Local diabetes association news in target European countries, Tandem's international social media channels for hiring/marketing activities. | SimilarWeb: Web traffic to Tandem's country-specific websites in new direct markets. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| U.S. Pump Shipments | Management explicitly stated that pump shipments will be the 'key indicator' of market progress in 2026, as reported revenue will be moderated by the PayGo transition. It reflects underlying demand and market expansion. | 12.5% |
| Gross Margin | The company is committed to 'delivering meaningful margin expansion' despite the PayGo transition's near-term revenue impact. Gross margin trajectory will show the effectiveness of pricing strategies and cost reductions. | Increased by 2 percentage points |
| Worldwide Sales | Despite anticipated near-term headwinds from the PayGo transition and international direct operations, overall sales growth indicates the company's ability to navigate these strategic shifts and expand its market. It's a key top-line indicator. | 15% |
Key QuestionsWill Tandem Diabetes Care's U.S. PayGo model demonstrate initial traction in Q1 2026, with pharmacy penetration rates for new pump shipments and existing custom
Will Tandem Diabetes Care's U.S. PayGo model demonstrate initial traction in Q1 2026, with pharmacy penetration rates for new pump shipments and existing customer supply orders meeting or exceeding internal expectations as new contracts become effective?
- Question 2
Will Tandem Diabetes Care provide a clear and positive update on the progress towards its Mobi Tubeless 510(k) submission in Q2 2026, reinforcing confidence in its planned second-half launch and competitive positioning?
- Question 3
How successfully will Tandem Diabetes Care execute the initial phase of its international direct operations expansion in Q1 2026, specifically in the U.K., Switzerland, and Austria, and will the associated distributor destocking headwind be managed within expectations?
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Modernizing commercial operations**: Management is focused on strengthening execution worldwide by expanding the U.S. sales team, updating sales processes, implementing new systems for efficiency, and expanding dedicated commercial efforts for people with type 2 diabetes. Internationally, they are transitioning to direct commercial operations in key markets like the U.K., Switzerland, and Austria to deepen relationships, improve pricing, and margins. 2. **Delivering new technology**: Tandem is committed to innovation, having launched Control-IQ+, FreeStyle Libre 3 Plus for t:slim, and Android Control for Mobi in 2025. For 2026, they plan multiple new product launches including Mobi internationally, Mobi integration with FreeStyle Libre 3 Plus, Dexcom's 15-day sensor integration, and the filing of a 510(k) for Mobi Tubeless. They also have a pipeline including SteadiSet, next-generation Mobi, and a fully closed-loop AID system. 3. **Reshaping the business model with pharmacy strategy and PayGo**: Management is accelerating efforts to increase pharmacy coverage for t:slim X2 and Mobi platforms and drive utilization of the pharmacy benefit. A key aspect is adopting a pay-as-you-go (PayGo) reimbursement structure, which eliminates upfront pump payments for customers, provides greater economic reimbursement for Tandem, and is expected to drive market expansion and profitability. | The overall takeaway of the call is that Tandem Diabetes Care had a strong finish to 2025, surpassing $1 billion in sales and achieving record Q4 results with double-digit growth and improved profitability. The company is undergoing a significant strategic transformation in 2026, particularly with the acceleration of its pharmacy strategy and the adoption of a pay-as-you-go (PayGo) reimbursement model in the U.S., and a transition to direct international operations. While these changes are expected to create near-term sales headwinds in 2026, management views them as crucial for long-term market expansion, accelerated growth, and enhanced profitability in 2027 and beyond. The tone of the call was largely **positive and confident**, with management emphasizing the strategic importance and long-term benefits of their initiatives despite the anticipated short-term revenue moderation. They highlighted strong product pipeline, operational efficiencies, and commitment to margin expansion. | For Q3 2025, worldwide sales grew 2.17% year-over-year. U.S. sales grew 2.50% year-over-year. International sales grew 1.80% year-over-year. This indicates a significant acceleration in year-over-year growth across all segments from Q3 2025 to Q4 2025. | 1. **The new PayGo business model and its implementation**: Analysts inquired about the context for the 20% of pumps going through pharmacy in 2026, current coverage and contracting, and the long-term goals for pharmacy penetration. Management responded that they have contracts with major PBMs (80% covered lives) but are focused on formulary access (currently 1/3 of lives covered). They expect low volume initially, scaling up to 20% of pump shipments through pharmacy in 2026, and eventually over 70% of sales in 2-3 years. They also clarified that the PayGo model eliminates upfront payments, reduces out-of-pocket costs for patients, and provides a more predictable revenue stream for Tandem. 2. **The protracted international transition to direct operations**: Analysts questioned why the international transition was taking longer than initially expected. Management explained that the process involves significant tasks like hiring sales forces, building infrastructure, and coordinating distributor separations, which is being staged over a two-year period (2026 and 2027) to manage risk. They are using the 2025 transitions as a playbook for future expansions and plan for a hybrid model in the long term. 3. **Confidence in accelerating new pump shipments in 2026 without Mobi Tubeless benefit**: Analysts asked about the drivers for the expected acceleration in new pump shipments given that Mobi Tubeless benefit isn't included in the revenue plan. Management expressed high confidence, citing the enhanced functionality of Mobi (multiple sensor integrations, Android/iOS, Tubeless implementation expected post-approval), expansion of Mobi and FreeStyle Libre 3 into OUS markets, improved sales force productivity from new systems, and the positive impact of the pharmacy channel. | Worldwide sales grew 15% year-over-year to $290 million. U.S. sales increased 14% year-over-year to $210 million. International sales grew 17% year-over-year to $80 million. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Tandem's Control-IQ+ algorithm is now indicated for people living with type 1 diabetes down to age 2 and for adults with type 2 diabetes, effectively doubling the company's addressable market. The company is expanding its dedicated commercial efforts for people with type 2 diabetes in the United States. Internationally, Tandem has launched direct commercial operations in the U.K., Switzerland, and Austria, with plans for further expansion into additional key European markets in 2026 and 2027. New product launches in 2026 include a scaled international launch of Mobi, Mobi integration with the FreeStyle Libre 3 Plus in the U.S., and Dexcom's 15-day sensor integration globally. A 510(k) submission with the FDA for a pregnancy indication for Control-IQ+ technology has also been made. The strategic shift to a pharmacy channel and pay-as-you-go reimbursement model is anticipated to drive market expansion by improving affordability and accessibility for customers. Additionally, the review of ADA guidelines on C-peptide testing by CMS is seen as a potential positive for substantially improving Medicare's access to pump technology for type 2 diabetes. | Tandem aims to maintain its leadership in Automated Insulin Delivery (AID) systems, a position it has held since the launch of Control-IQ in 2020. The company is developing Mobi Tubeless, which it describes as the 'world's first patch pump with extended wear technology' and Tandem's first patch pump offering. It was noted that currently 'there's nobody competing with our patch competitor' in terms of a device with the same form factor, but Mobi Tubeless is expected to differentiate itself by being available in the pharmacy channel and featuring a 'better algorithm', which is anticipated to perform 'quite well'. | A significant trend in the broader industry, particularly in diabetes management, is the shift towards pharmacy access and pay-as-you-go reimbursement models. This approach is noted to offer customers lower average out-of-pocket costs and easier onboarding, while providing healthcare providers with a streamlined prescription process and payers with enhanced data visibility and improved member outcomes. The company's experience in 2025 confirmed the benefits of pharmacy access, leading to an acceleration of this strategy. Regulatory developments, such as the ADA guidelines on C-peptide testing and the Senate's request for CMS to review the National Coverage Determination (NCD) for insulin pumps by August 2026, are also impacting market access for diabetes devices. | Tandem is positioned for sustainable growth and profitability in 2026 and beyond, driven by modernized commercial operations, new technology, and a reshaped business model. The company plans to further expand its direct international operations in 2026 and 2027, using its initial transitions as a playbook. Multiple new product launches are scheduled for Q2 2026, including Mobi internationally, Mobi integration with FreeStyle Libre 3 Plus in the U.S., and Dexcom's 15-day sensor integration globally. A 510(k) submission for Mobi Tubeless is planned for Q2 2026, with a launch expected in the second half of the year. Tandem intends to begin a pivotal trial for a fully closed-loop algorithm later this year, supporting an FDA filing in 2027. In the U.S., the company is accelerating its pharmacy strategy, aiming for the majority of pump shipments to transition to the pharmacy channel within 2 to 3 years. Long-term objectives include achieving accelerated sales growth with a gross margin of at least 65% and an operating margin of 25%. Free cash flow is expected to be neutral in 2026, with a ramp-up to a positive position in 2027. | Medical | A broader theme emerging is the fundamental shift in reimbursement and distribution models within the medical device industry, moving towards 'pay-as-you-go' and pharmacy channels. This trend aims to reduce upfront patient costs, streamline healthcare provider processes, and provide manufacturers with more predictable, higher-value revenue streams over time, potentially influencing other medical technology sectors beyond diabetes. | 2025 was a defining year for Tandem, where we surpassed the milestone of $1 billion in sales. Control-IQ+, our next-generation automated insulin delivery algorithm... doubles our addressable market. our pipeline is the most exciting in diabetes. PayGo can be a key driver for accelerated pump adoption as it eliminates the upfront payment. we double or more than double the revenue, the lifetime revenue from a patient. accelerated growth in 2027 and beyond. we will have a device that has the same form factor. It will be in the pharmacy channel and has a better algorithm. So we expect that to do quite well. | There are risks and uncertainties that could cause actual results to differ materially. 2026 sales growth may be more moderated. This incorporates $70 million to $80 million of pricing headwinds. adjusted EBITDA to be negative 2% to negative 1% of sales in Q1. the number of opportunities will decline here in the coming years a little bit from what we've seen before. | The company hired talent in the U.K., Switzerland, and Austria to support the transition to direct commercial operations in those countries. Tandem is also 'constantly looking for opportunities and ways to reduce the need to hire more people in the future and just better serve our customers with a lower headcount base going forward,' indicating a focus on efficiency and optimized staffing. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-20 | Tandem's Q4 2025 call highlighted a PayGo pharmacy transition, direct European expansion, and a robust product pipeline (Mobi Tubeless, Libre 3 Plus, Dexcom integration). Management projected 2026 revenue growth of 10-11% with gross margins rising toward 60% by year-end and 5-6% adjusted EBITDA; 2027-28 upside depends on payor adoption and continued innovation. The stock initially surged vs SPY on the plan but finished modestly lower as near-term headwinds emerged. | Other | Mixed | https://investors.tandemdiabetescare.com/news-releases/news-release-details/tandem-diabetes-care-reports-fourth-quarter-and-year-end-2025-results | False | +15.02% (vs SPY: +16.04%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| TNDM_f826e8b2 | in 2026 | 2026-01-01 | 2026-12-31 | Full implementation and operationalization of new sales systems in the United States. | Expected to provide significant efficiencies and benefits to the sales team, potentially impacting US sales growth and productivity. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_709c0ea7 | in the fourth quarter | 2026-10-01 | 2026-12-31 | Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions. | Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_f62815e7 | second quarter | 2026-04-01 | 2026-06-30 | Scaled international launch of the Mobi insulin pump. | Expands the market for Mobi globally, potentially driving international sales growth and competitive positioning. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_25623f39 | second quarter | 2026-04-01 | 2026-06-30 | Launch of Mobi insulin pump integration with the FreeStyle Libre 3 Plus continuous glucose monitor in the U.S. | Enhances Mobi's offering with a highly sought-after sensor integration, potentially driving US sales and competitive advantage. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_ec4ae537 | second quarter | 2026-04-01 | 2026-06-30 | Global launch of Dexcom's 15-day sensor integration on both Tandem's pumps and platforms. | Improves user experience and competitive offering across Tandem's product portfolio, potentially driving sales and customer retention. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_99373d95 | second quarter | 2026-04-01 | 2026-06-30 | Submission of 510(k) application to the FDA for Mobi Tubeless, Tandem's first patch pump offering. | A critical regulatory step towards commercializing a novel product that could significantly expand Tandem's addressable market and competitive position. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_82e30c2b | second half of the year | 2026-07-01 | 2026-12-31 | FDA clearance for Mobi Tubeless, enabling its commercial launch. | Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_a7005c10 | second half of the year | 2026-07-01 | 2026-12-31 | Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device. | Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_e141eabd | recently submitted a 510(k) | 2026-03-01 | 2026-12-31 | FDA clearance for Control-IQ+ technology with a pregnancy indication. | Expands the indicated use of Control-IQ+, potentially increasing its addressable market and sales by serving a new patient population. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_8eea9c45 | later this year | 2026-07-01 | 2026-12-31 | Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm. | A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_66b9a22c | beginning late in the first quarter and scaling over the course of 2 to 3 years | 2026-03-01 | 2029-02-20 | Full implementation and scaling of the pay-as-you-go (PayGo) reimbursement model in the pharmacy channel for both t:slim X2 and Mobi platforms. | This transformational business model change is expected to drive market expansion by reducing upfront costs for customers and improve long-term profitability through higher recurring supply revenue, despite a near-term sales headwind of $70M-$80M in 2026. | Ticker | 2026-02-20 | earnings_transcript |
| TNDM_6065a6be | August of '26 | 2026-08-01 | 2026-08-31 | CMS decision on the National Coverage Determination (NCD) for C-peptide testing, following a request from the Senate. | A favorable decision would substantially improve Medicare access for people with Type 2 diabetes, expanding Tandem's addressable market and potentially driving new pump starts in this segment. | Theme | 2026-02-20 | earnings_transcript |